OncoMatch/Clinical Trials/NCT07081646
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
Is NCT07081646 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies AZD0120 for relapsed al amyloidosis.
Treatment: AZD0120 — Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Disease stage
Excluded: Stage MAYO STAGE IIIB
Measurable hematologic disease: dFLC > 20 mg/L or serum M-protein > 5g/L; Mayo Stage IIIb AL amyloidosis [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-plasma cell-directed therapy
Relapsed disease or refractory disease defined as a need for additional therapy after at least 1 line of anti-plasma cell-directed therapy.
Cannot have received: CAR-T cell therapy
Prior CAR T cell therapy directed at any target
Cannot have received: BCMA-targeting therapy
Prior BCMA-targeting therapy
Cannot have received: T cell engaging therapy
Prior treatment with any FDA approved or investigational T cell engaging therapies (including T cell-directed bispecific or trispecific therapies) at any target within the last 6 months.
Lab requirements
Cardiac function
NYHA class III or IV excluded; Systolic blood pressure <100mmHg excluded; Oxygen saturation <95% on room air excluded
Oxygen saturation < 95% on room air; Systolic blood pressure <100mmHg; NYHA class III or IV
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Phoenix, Arizona
- Research Site · San Francisco, California
- Research Site · Tampa, Florida
- Research Site · Boston, Massachusetts
- Research Site · Detroit, Michigan
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07081646 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy, BCMA-targeting therapy, T cell engaging therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages